Overview
Amneal Pharmaceuticals, Inc., based in the United States, operates primarily in the generic and specialty pharmaceutical sectors. Founded in 2002, the company has developed a robust portfolio that includes a variety of generic medicines, along with specialty pharmaceutical products focusing on central nervous system disorders, endocrinology, and oncology. Amneal has emphasized innovation in its operational strategy, leading to significant growth through both research and development and strategic acquisitions. Notably, the company has been active in expanding its injectable and inhalation product lines, aiming to meet diverse market demands globally. This strategic focus is complemented by an ongoing commitment to enhancing patient access to affordable medications, which underscores Amneal’s integral role in the pharmaceutical industry.
Basic Stats
The share price of Amneal Pharmaceuticals, Inc. as of September 5, 2025 is $9.62 / share. This is an increase of 0.58% from the prior week. The market cap (or net worth) of Amneal Pharmaceuticals, Inc. as of September 5, 2025 is $3,016.60 MM.
The Factor Analysis chart (below right) shows a view of Amneal Pharmaceuticals, Inc. from a variety of lenses. Each factor shows how well the company ranks against all other companies in the Fintel global investing universe. Factor scores range from zero to 100, with 100 being most desirable, and 50 being average.
For example, a company with a Value Score of 100 would be the most undervalued company in our database. A company with a Value Score of zero would be the most overvalued.
| Market Cap | 3,016.60 MM |
| EV | 5,478.44 MM |
| Shares Out. | 313.74 MM |
| Earnings Date | |
| EPS (TTM) | 0.01 |
| Dividend Yield | |
| Ex-Dividend Date | |
| Borrow Rate | 0.25 |
| Short Shares Avail. | 10.00 MM |
| Short Interest | 4.78 MM |
| Short Float | 2.83 % |
| Days to Cover | 4.45 days |
| Risk Free Rate | 4.17 % |
| Price Change (1 yr) | 13.79 % |
| Volatility (1 yr) | 0.33 |
| Beta | 0.94 |
| Sharpe Ratio (1 yr) | 0.29 |
| Sortino Ratio (1 yr) | 0.50 |
| PE Ratio | 893.81 |
| Price/Book | -64.55 |
| Price/TBV | -2.22 |
| Book/Market | -0.02 |
| EBIT/EV | 0.02 |
| EBIT(3yr avg)/EV | -0.00 |
| ROA | 0.00 |
| ROE | |
| ROIC | 0.00 |
| CROIC | 0.01 |
| OCROIC | 0.14 |
| Implied Volatility | 49.15 % |
| Put/Call OI Ratio | 0.07 |
Factor Scores range from 0 to 100, with 100 being most desirable. Larger circles are better. In situations where we have no data (e.g. no insider trades), we plot the score at 50 to avoid penalizing companies. However, a company that does not pay dividends will get a Dividend Score of Zero. Additionally, we inverted volatility to create a "stability" metric which is better when higher.
Price Target
The average one-year price target for Amneal Pharmaceuticals, Inc. is $12.24. The forecasts range from a low of $11.11 to a high of $13.65. A stock’s price target is the price at which analysts consider it fairly valued with respect to its projected earnings and historical earnings. Analysts typically set price targets that correspond to their buy or sell recommendations.
Update Frequency: Monthly
Stock Upgrades/Downgrades
This card shows analyst upgrades/downgrades for Amneal Pharmaceuticals, Inc.. An analyst rating is a classification that gives investors a sense of analyst sentiment about the direction and performance of an equity - usually a stock - over a period of time, typically 12 months.
The standard analyst ratings are generally as follows:
- Buy/Overweight/Outperform - Any of these ratings conveys an analyst’s belief that the stock is likely to outperform a market index (e.g. the S&P 500).
- Hold/Equal-Weight/Market Perform - Any of these ratings conveys an analyst’s belief that the stock is likely to perform in line with a market index.
- Sell/Underweight/Underperform - Any of these ratings suggest that an analyst believes the stock is likely to underperform a market index.
When an analyst upgrades a stock, they are signaling that the company’s fundamentals are being undervalued by investors. It could also mean they believe the market is underestimating the company’s potential. The opposite is true when a stock receives a downgrade.
The average rating of each individual analyst’s rating is the consensus rating for a stock. This gives investors a broader sense of the overall sentiment for that stock.
| Date | Analyst | Prior | Latest Recommendation |
Action |
|---|---|---|---|---|
| 2022-08-08 | Goldman Sachs | Buy | Maintains | |
| 2022-05-12 | Goldman Sachs | Buy | Maintains | |
| 2021-03-08 | Goldman Sachs | Sell | Buy | Upgrade |
| 2020-12-14 | Guggenheim | Neutral | Buy | Upgrade |
| 2020-11-09 | SVB Leerink | Market Perform | Maintains | |
| 2020-10-09 | Piper Sandler | Overweight | Maintains | |
| 2020-07-27 | Goldman Sachs | Sell | Initiate | |
| 2020-05-13 | SunTrust Robinson Humphrey | Buy | Maintains | |
| 2020-05-12 | SVB Leerink | Market Perform | Maintains | |
| 2020-05-12 | Guggenheim | Sell | Neutral | Upgrade |
| 2020-04-02 | Morgan Stanley | Equal-Weight | Maintains | |
| 2020-02-27 | SunTrust Robinson Humphrey | Buy | Maintains | |
| 2020-01-02 | RBC Capital | Sector Perform | Maintains | |
| 2019-12-12 | Raymond James | Outperform | Market Perform | Downgrade |
| 2019-11-12 | JP Morgan | Neutral | Underweight | Downgrade |
| 2019-11-11 | BMO Capital | Market Perform | Maintains | |
| 2019-11-07 | SVB Leerink | Outperform | Market Perform | Downgrade |
| 2019-11-07 | Raymond James | Outperform | Maintains | |
| 2019-09-12 | Guggenheim | Sell | Initiate | |
| 2019-08-06 | BMO Capital | Market Perform | Maintains | |
| 2019-07-22 | SVB Leerink | Market Perform | Outperform | Upgrade |
| 2019-07-11 | SunTrust Robinson Humphrey | Buy | Maintains | |
| 2019-07-11 | RBC Capital | Outperform | Sector Perform | Downgrade |
| 2019-07-10 | Raymond James | Strong Buy | Outperform | Downgrade |
| 2019-07-08 | Piper Jaffray | Neutral | Overweight | Upgrade |
| 2019-06-11 | Barclays | Equal-Weight | Initiate | |
| 2019-05-21 | Raymond James | Market Perform | Strong Buy | Upgrade |
| 2019-05-10 | BMO Capital | Market Perform | Maintains | |
| 2019-03-20 | SunTrust Robinson Humphrey | Buy | Initiate | |
| 2018-12-14 | Morgan Stanley | Overweight | Equal-Weight | Downgrade |
| 2018-10-16 | SunTrust Robinson Humphrey | Buy | Hold | Downgrade |
| 2018-10-03 | Morgan Stanley | Overweight | Overweight | Maintains |
| 2018-08-22 | B. Riley FBR | Buy | Buy | Maintains |
| 2018-08-14 | Canaccord Genuity | Hold | Hold | Maintains |
| 2018-08-13 | RBC Capital | Sector Perform | Outperform | Upgrade |
| 2018-08-10 | BMO Capital | Market Perform | Market Perform | Maintains |
| 2018-07-23 | Morgan Stanley | Overweight | Initiate | |
| 2018-06-22 | B. Riley FBR | Buy | Initiate | |
| 2018-05-18 | JP Morgan | Neutral | Initiate | |
| 2023-03-03 | Goldman Sachs | Buy | Maintains | |
| 2023-03-03 | BMO Capital | Market Perform | Maintains | |
| 2023-03-10 | Barclays | Overweight | Maintains | |
| 2023-03-29 | Truist Securities | Buy | Maintains | |
| 2023-05-08 | Piper Sandler | Overweight | Maintains | |
| 2023-08-07 | Truist Securities | Buy | Buy | Maintains |
| 2023-08-07 | Barclays | Overweight | Overweight | Maintains |
| 2023-08-07 | Piper Sandler | Overweight | Overweight | Maintains |
| 2023-09-06 | Truist Securities | Buy | Buy | Reiterate |
| 2023-11-08 | Truist Securities | Buy | Buy | Maintains |
| 2024-01-29 | Barclays | Overweight | Overweight | Maintains |
| 2024-05-06 | Goldman Sachs | Buy | Buy | Maintains |
| 2024-05-06 | Truist Securities | Buy | Buy | Reiterate |
| 2024-03-21 | Piper Sandler | Overweight | Overweight | Maintains |
| 2024-03-04 | Goldman Sachs | Buy | Buy | Maintains |
| 2025-02-24 | JP Morgan | Neutral | Overweight | Upgrade |
| 2024-10-02 | Truist Securities | Buy | Buy | Maintains |
| 2025-03-03 | Barclays | Overweight | Overweight | Maintains |
| 2024-08-12 | Truist Securities | Buy | Buy | Maintains |
| 2024-11-11 | Piper Sandler | Overweight | Overweight | Maintains |
| 2024-09-06 | JP Morgan | Underweight | Neutral | Upgrade |
| 2024-08-13 | Barclays | Overweight | Overweight | Maintains |
